4.6 Article

Insights into clinical and diagnostic findings as well as treatment responses in patients with mucous membrane pemphigoid: A retrospective cohort study

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2021.11.061

关键词

autoimmune blistering disease; autoimmune bullous diseases; case series; clinical characteristics; immunology; laminin-332; malignancy; mucous membrane pemphigoid

向作者/读者索取更多资源

Patients with mucous membrane pemphigoid present with heterogeneous clinical manifestations, with new symptoms potentially developing during the disease course. Cancer screening should be considered for patients with autoantibodies against laminin-332.
Background: The variable clinical severity of mucous membrane pemphigoid (MMP) often leads to diagnostic and therapeutic delays. Objective: To describe the characteristics of a large cohort of patients with MMP. Methods: A retrospective review of clinical and diagnostic characteristics as well as treatment responses in 145 patients with MMP. Results: Monosite involvement was seen in 41.4% and multisite involvement in 58.6% of the patients. The oral mucosa was affected in 86.9% of the patients, followed by the ocular mucosa (30.3%), skin (26.2%), genital mucosa (25.5%), nasal mucosa (23.4%), and pharyngeal and/or laryngeal mucosa (17.2%). Ocular disease developed during the disease course in 41.7% of patients with initially other mucosal site involvement. The malignancy rate was significantly higher in patients with autoantibodies against laminin-332 than in patients with MMP without laminin-332 autoantibodies (35.3% vs 10.9%, respectively; P = .007). Systemic immunosuppressive or immunomodulatory therapy was administered to 77.1% of the patients, mainly to patients with multisite (P<.001), ocular (P<.001), and pharyngeal and laryngeal involvement (P = .002). The remaining patients (22.9%) received topical therapy. Adverse events were frequently reported. Limitations: Retrospective design. Conclusion: Patients with MMP present with a heterogeneous clinical presentation, and new symptoms may develop during the disease course. Cancer screening should be considered for patients with MMP and, in particular, for those with autoantibodies against laminin-332.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据